Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ).
Pharmaron Beijing Co., Ltd. has announced the schedule for its Annual General Meeting (AGM) of 2024, set to take place on June 20, 2025, in Beijing. The AGM will address various resolutions including the approval of the 2024 financial statements, profit distribution, and amendments to several company policies. The meeting will also cover the engagement of auditors for 2025 and the adoption of a new H Share Award and Trust Scheme. These resolutions are expected to impact the company’s operational strategies and governance structure, influencing its market positioning and stakeholder relations.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a joint stock company based in China, primarily engaged in providing comprehensive drug research and development services. The company focuses on offering a wide range of services including laboratory and manufacturing solutions to the pharmaceutical and biotech industries.
Average Trading Volume: 8,222,394
Technical Sentiment Signal: Buy
Current Market Cap: HK$40.73B
Learn more about 3759 stock on TipRanks’ Stock Analysis page.